First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

Purpose: To assess the morphological and functional outcomes within the first year of treatment with intravitreal brolucizumab for refractory neovascular age-related macular degeneration (nAMD).Methods: This retrospective study included 21 eyes from 19 patients with refractory nAMD followed for 12 m...

Full description

Bibliographic Details
Main Authors: Alaa Din Abdin, Wissam Aljundi, Khalil El Jawhari, Shady Suffo, Isabel Weinstein, Berthold Seitz
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Pharmacology
Subjects:
neovascular age-related macular degeneration (nAMD)
intraocular inflammation
intravitreal brolucizumab
switching therapy
refractory macular edema
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.860784/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.860784/full

Similar Items